Aberdeen University spin-out Elasmogen has announced the securing of follow-on equity investment from Deepbridge Capital totalling £2 million, taking the company’s total investment in Elasmogen to £3.15 million. The biopharmaceutical company revealed that the funding will be used to accelerate the development of the company’s next generation biologics for “site-specific delivery and treatment of diseases refractory to existing drug therapies.” Source: Pharmatimes 13/1/2020